+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma



Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma



Gynecologic Oncology 110(3): 280-285



To compare the disease-free survival (DFS) of patients with surgical stage 1, intermediate-risk endometrial adenocarcinoma (EAC) treated with primary surgery with or without adjuvant vaginal vault brachytherapy (VVBT). A retrospective chart review identified 575 patients with stage 1B, 1C or 2A endometrial cancer who had surgery between 1990 and 2004. All patients were surgically staged and 259 patients received postoperative VVBT. The date and site of first recurrence were considered the primary statistical endpoints and were analysed by univariate and multivariate Cox models. Subgroups of patients stratified by substage and grade were created and Log-rank tests using vaginal recurrence as the endpoint were calculated within these groups. After a mean follow-up period of 72 months (95%-confidence interval (CI): 68 to 75 months) a total of 43 (7.5%) patients developed recurrence. Multivariate analysis demonstrated that increasing patient's age at diagnosis and stage 1C or 2A disease were independent risk factors for recurrence whereas the grade of differentiation and the type of treatment (surgery alone vs. surgery followed by postoperative VVBT) were not associated with a change in DFS. Analysis within the subgroups stratified by substage and grade did not even reveal a trend towards improved local control with VVBT. Postoperative VVBT was not associated with a measurable reduction in the risk of recurrence in surgical stage 1, intermediate-risk endometrial cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052650856

Download citation: RISBibTeXText

PMID: 18777645

DOI: 10.1016/j.ygyno.2008.05.028


Related references

Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecologic Oncology 79(3): 490-494, 2000

Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial. International Journal of Radiation Oncology Biology Physics 38(2): 373-380, 1997

Assessing Efficacy of Adjuvant Vaginal Vault Brachytherapy Among Intermediate-Risk Stage I Endometrial Cancer Patients. International Journal of Radiation Oncology*biology*physics 84(3): S455-S456, 2012

Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma. Gynecologic Oncology 81(2): 193-195, 2001

Vaginal Vault Brachytherapy Alone As Adjuvant Treatment For Node-Negative Stage Ii Endometrial Cancer Manitoba Experience. Radiotherapy and Oncology 92: S45-S46, 2009

Vault high dose rate brachytherapy for low to intermediate risk endometrial adenocarcinoma completely resected. International Journal of Cancer Suppl. (13): 461, 2002

External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecologic Oncology 106(1): 215-220, 2007

Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. International Journal of Gynecological Cancer 20(4): 564-569, 2010

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375(9717): 816-823, 2010

Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy. Oncology 96(5): 235-241, 2019

Comprehensive staging surgery including complete pelvic and para-aortic lymphadenectomy followed by adjuvant vaginal brachytherapy improves survival rates for intermediate-risk endometrial cancer patients. Gynecologic and Obstetric Investigation 74(1): 68-75, 2012

Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer. Journal of Contemporary BrachyTherapy 7(5): 357-362, 2015

Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma. Journal of Contemporary BrachyTherapy 10(2): 105-114, 2018

Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. BrachyTherapy 7(2): 195-199, 2008

Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. Journal of Clinical Oncology 26(15_Suppl): Lba5503-Lba5503, 2016